# OnCo record ratio-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ratio-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ratio-therapeutics" ;
  schema:name "Ratio Therapeutics"@en ;
  schema:description "Ratio Therapeutics, of Boston, designs small molecules that carry a radioactive isotope to fibroblast activation protein, a protein on the supporting tissue of sarcomas and other solid tumours, so radiation is delivered from inside the body. Its lead, an actinium-225 radioligand, is in the ATLAS phase 1/2 trial in advanced sarcomas."@en ;
  schema:url <https://onco.cc/companies/ratio-therapeutics/>, <https://ratiotx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://ratiotx.com/>, <https://ratiotx.com/2026/07/31/ratio-therapeutics-closes-70-million-series-c-financing-to-advance-clinical-development-of-targeted-radiotherapeutics-pipeline-and-expand-manufacturing-infrastructure/>, <https://ratiotx.com/news1/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/fap/> .